Roth S H
Eur J Rheumatol Inflamm. 1982;5(2):258-69.
The efficacy and safety of benoxaprofen and sulindac were compared in patients with rheumatoid arthritis and osteoarthritis. A double-blind, crossover protocol was used with three placebo periods. Fixed doses--600 mg of benoxaprofen once a day and 200 mg of sulindac twice a day--were used. Rheumatoid arthritis patients showed significant improvement in most measurements with both drugs, but overall results favored benoxaprofen, particularly in erythrocyte sedimentation rate and physician's global assessment. Results were fairly equal in osteoarthritis patients. Propoxyphene consumption was less during the benoxaprofen therapy period for both groups of patients. Adverse reactions in combined rheumatoid arthritis and osteoarthritis patients generally were mild to moderate. Gastrointestinal complaints were more common with sulindac, while skin reactions were more common with benoxaprofen. No serious abnormalities in laboratory values were noted.
对类风湿性关节炎和骨关节炎患者比较了苯恶洛芬和舒林酸的疗效及安全性。采用双盲交叉方案，设有三个安慰剂期。使用了固定剂量——苯恶洛芬每日600毫克一次，舒林酸每日200毫克两次。类风湿性关节炎患者在使用两种药物时，多数测量指标均有显著改善，但总体结果更倾向于苯恶洛芬，尤其是在红细胞沉降率和医生的整体评估方面。骨关节炎患者的结果相当。两组患者在苯恶洛芬治疗期间的丙氧芬消耗量均较少。类风湿性关节炎和骨关节炎合并患者的不良反应一般为轻至中度。舒林酸更常见胃肠道不适，而苯恶洛芬更常见皮肤反应。未发现实验室值有严重异常。
